ReviewLupus2013
Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.
Review in Lupus, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 61 citations in OpenAlex.
- Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0).Biologics : targets & therapy · 2025Article
- Rowell syndrome.Postepy dermatologii i alergologii · 2023Article
- Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.American journal of clinical dermatology · 2023Review
- Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist.The Journal of rheumatology · 2023Review
- Recent advances in cutaneous lupus.Journal of autoimmunity · 2022Review
- B cell depletion therapy using rituximab to induce long-term remission of recalcitrant skin lesions of subacute cutaneous lupus erythematosus.BMJ case reports · 2022Article
- Off-Label Uses of Rituximab in Dermatology.Current dermatology reports · 2022Review
- Immunogenetics of Lupus Erythematosus.Advances in experimental medicine and biology · 2022Article
- Utilization of Rituximab for Refractory Rowell Syndrome.Case reports in rheumatology · 2021Article
- Cutaneous Lupus Erythematosus: Progress and Challenges.Current allergy and asthma reports · 2020Review
- Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies.The Yale journal of biology and medicine · 2020Review
- Current Insights in Cutaneous Lupus Erythematosus Immunopathogenesis.Frontiers in immunology · 2020Review
- Cutaneous lupus erythematosus: A review of the literature.International journal of women's dermatology · 2019Review
- Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies.Nature reviews. Rheumatology · 2019Review
- New therapeutic strategies in systemic lupus erythematosus management.Nature reviews. Rheumatology · 2019Review
- Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.JAMA dermatology · 2018Observational
- Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus.Anais brasileiros de dermatologia · 2018Article
- Pathogenesis of Skin Injury of Systemic Lupus Erythematosus.Current rheumatology reports · 2018Review
- CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Clinical reviews in allergy & immunology · 2017Review
- Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.Expert review of clinical immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous manifestations occur frequently in systemic lupus erythematosus (SLE) and are pathognomonic in subacute-cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE). Although B-cell depletion therapy (BCDT) has demonstrated efficacy in SLE with visceral involvement, its usefulness for patients with predominant skin manifestations has not been fully established. In this single-centre, retrospective study 14 consecutive SLE, one CCLE and two SCLE patients with recalcitrant skin involvement were treated with 2 × rituximab 1 g, and 1 × cyclophosphamide 750 mg. Six months after BCDT, nine of 17 (53%) patients were in complete (CR) or partial remission (PR). Relapses occurred in 12 patients (71%) at a mean time of 10 ± 1.8 months after BCDT. A second cycle of BCDT achieved a more sustained remission in seven of nine patients (78%) lasting for a mean time of 18.4 ± 2.7 months. Minor adverse events were experienced by three patients. Mean follow-up was 30 months. Our own results and the literature review demonstrate that BCDT based on rituximab is well tolerated and may be effective for cutaneous lesions of lupus erythematosus. Randomized controlled trials are necessary to further evaluate the value of BCDT for this group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.